The single-institution study was undertaken using the same unified method for tumor staging and identical treatment regimens and the same protocol for follow-up of blood sampling and administration of G-CSF, and we provided supportive care throughout, which enabled us to confirm important predictive factors. The gene discussed is CSF3; the disease is neoplasm.